Search

Search Constraints

You searched for: Author/Creator Chessell, Iain

Search Results

1. [O2–09–02]: EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA‐AMYLOID 42 (Aβ42)‐SPECIFIC ANTIBODY, IN PATIENTS WITH MILD‐MODERATE ALZHEIMER'S DISEASE. (1st July 2017)

2. [P1–074]: PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA‐AMYLOID 42 (Aβ42). (1st July 2017)

3. [P3–036]: MEDI1814, A HIGH‐AFFINITY ANTIBODY DIRECTED TO THE C‐TERMINUS OF AβX‐42, ABROGATES SYNAPTIC PLASTICITY DISRUPTION CAUSED BY SYNTHETIC OR AD BRAIN‐DERIVED Aβ SOLUBLE ASSEMBLIES IN VIVO. (1st July 2017)

4. Antibodies binding the head domain of P2X4 inhibit channel function and reverse neuropathic pain. Issue 9 (September 2019)

5. Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice. Issue 3 (27th February 2019)

6. Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain. Issue 3 (March 2018)

7. Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. Issue 3 (23rd March 2019)

9. Genetic Background Strongly Influences the Bone Phenotype of P2X7 Receptor Knockout Mice. (9th August 2012)

10. Genetic Background Strongly Influences the Bone Phenotype of P2X7 Receptor Knockout Mice. (9th August 2012)